Hormone Refractory Prostate Cancer (HRPCA) Market

Hormone Refractory Prostate Cancer (HRPCA) Market Size by Treatment Type (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery), End-User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), Regions, Global Industry Analysis, Share, Growth, Trends, and Forecast 2021 to 2028

Base Year: 2020 Historical Data: 2018-19
  • Report ID: TBI-12543
  • Published Date: Oct, 2021
  • Pages: 234
  • Category: Healthcare
  • Format: PDF
Buy @ $4700.00 Request Sample PDF

Global hormone refractory prostate cancer (HRPCA) market is expected to reach USD 18.35 billion by 2028, at a CAGR of 9.64% from 2021 to 2028. Global hormone refractory prostate cancer (HRPCA) market is witnessing a considerable growth owing to promising pipeline drugs.

Market Overview:

Hormone refractory prostate cancer (HRPC) is the advanced form of prostate cancer in which condition does not respond to the treatment of hormone. Hormone refractory prostate cancer (HRPC) is also known as Castrate-Resistant Prostate Cancer (CRPC). Normally early-stage prostate cancer require normal level of testosterone to grow, but this cancer does grow even when the testosterone level is kept very low, and that’s why it is called Castrate-Restraint Prostate Cancer (CRPC). The prostate cancer at initial stages usually does not show any symptoms. In the advancing stages, the symptoms can be seen. The prostate cancer can be identified in a CT scan or bone scan. For diagnosis of Hormone Refractory Prostate Cancer(HRPC) prostate biopsy is the solution. The prevalence of this cancer, advancement in technologies and high unmet requirement are some of the factors fuelling Hormone Refractory Prostate Cancer Market. As two of the best emerging economies are in the Asia Pacific region, there is a great scope of this market in this region. The emerging economies like India and China, where the disposable income of the people are increasing, there is a great opportunity for this market. As people with increasing per capita income will look for the best treatment to get cured. So this region holds a promising future for the market.  The advancement in technologies, the promising drugs in the pipeline are also the factors driving this market. Also, the rise in the awareness of the people about this cancer and the types of treatment for it will also drive this market. However, the high cost of the treatment, uncertain reimbursement policies and little life expectancy are some of the factors that are acting as a restraint for the market. The prostate cancer mostly affects old age people. So the rising geriatric population in the developed economies could show rising cases of Hormone Refractory Prostate Cancer (HRPCA), which will fuel this market. 

Get an overview of this study by requesting a free sample

Market Dynamics:

Drivers:
  • Promising pipeline drugs

The emerging economies like India and China, where the disposable income of the people are increasing, there is a great opportunity for this market. As people with increasing per capita income will look for the best treatment to get cured. So this region holds a promising future for the market.  The advancement in technologies, the promising drugs in the pipeline are also the factors driving this market. Also, the rise in the awareness of the people about this cancer and the types of treatment for it will also drive this market.

  • Evolving patterns of treatment with increase in patent awareness

As mentioned before, with the increase in disposable income among people, the health concern among people have also risen. Also in the developing countries, there is a large scope with the large undiagnosed patient population, rise in government funding for cancer, and developing awareness about prostate cancer would be the reasons accountable for d market growth.

 

Restraints:
  • High pricing of CRPC drugs

Issues such as high pricing of CRPC drugs, inexact reimbursement policies, , and are likely to suspend the market growth. These are the factors that are restraining the market. But the major factor is the premium pricing which is blocking or making people reluctant of the treatment compounded with the reimbursement policies, which is also very uncertain.

Opportunities:
  • Treatment in emerging economies

There are many untapped region for this market. But because of the high price of the treatment, the companies would focus on the emerging countries where the per capita income of the people are increasing. The biggest economies of the world India and China would be the most important region for this market. As the disposable income of the people have increase, they are looking for better quality of life which include better health care and better treatment. The increase in the education rate in the emerging economies are creating the awareness about the types of cancer and the types of treatment required for the treatment. This sets a good soil for the expansion of this market in this region.

Segmentation Analysis:

The global Hormone Refractory Prostate Cancer (HRPCA) market has been segmented based on treatment type, end-user, and regions.

  • Treatment type segments include chemotherapy, hormonal therapy, immunotherapy, radiation therapy, surgery, and others. The hormonal therapy segment is accounted for the largest market share of around 57.85% in 2020. This methodology is utilized due to the availability of treatment in most clinics and hospitals. The major consensus resorts to this treatment method because of the high amount of successful research in this technique.
  • The end-user segment includes Hospitals, Ambulatory Surgical Centers, Specialty Clinics and Others. Hospitals had held the largest market share of 37.83% in the year 2020. This is because cancer treatments happen in hospitals and in Cancer specialized hospitals.
Regional Segmentation Analysis:

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and the Middle East and Africa. North America is accounting for the largest market share of 33.38% in 2020.

  • North America captured a sizeable share of the regional Hormone Refractory Prostate Cancer (HRPCA) vertical with a share of over 33.38%, owing to the highly developed treatment scenarios in this region.
  • Asia-Pacific is forecasted to have the highest CAGR of 9.84% during the forecast period. The biggest economies of the world India and China would be the most important region for this market. As the disposable income of the people have increase, they are looking for better quality of life which include better health care and better treatment. The increase in the education rate in the emerging economies are creating the awareness about the types of cancer and the types of treatment required for the treatment.

The North America Hormone Refractory Prostate Cancer (HRPCA) Market Share in 2020- 33.38%

 

www.thebrainyinsights.com

Check the geographical analysis of this market by requesting a free sample

Competitive Analysis:

The key players are now concentrating on implementing strategies such as adopting new technology, product innovations, mergers & acquisitions, joint venture, alliances and partnerships to improve their market position in the global Hormone Refractory Prostate Cancer (HRPCA) industry.

For instance, in June 2018, Sanofi announced that it had completed the acquisition of Ablynx, a pharmaceutical company based in Ghent, Belgium, that develops therapeutic proteins based on single-domain antibody fragments. This acquisition would benefit Sanofi in obtaining a stronger foothold in the industry of medicine.

For instance, in 2017, Bioverativ Inc. acquired True North Therapeutics. The acquisition is in the direction of Bioverativ’s vision of becoming the leading rare disease company, concentrated on blood disorders.

List of Key Market Players:

  • AbbVie Inc.
  • AcceleronPharma Inc.
  • AB Science SA
  • AstraZeneca Plc.
  • AstellasPharma Inc.
  • Boston Biomedical Inc.
  • Dendreon Corporation
  • Sanofi S.A
  • Johnson & Johnson
  • BioverativInc

Key Target Audience

  • Hospitals
  • Clinics
  • Government Authorities
  • Research Organization
  • Ambulatory Surgical Centers

Report Description:

  • Global Hormone Refractory Prostate Cancer (HRPCA) Market, Industry Analysis, Trends, Analysis and Forecast, 2021 to 2028 is a forthcoming/imminent research report which is to be published by The Brainy Insights.
  • 2020 is considered as the base year of the report. 2018 and 2019 are considered as the historic years and 2021 to 2028 are the forecast years. The global Hormone Refractory Prostate Cancer (HRPCA) market is based on revenue (USD Million/Billion), volume and price. The report incorporates the market study on the basis of revenue, and volume. The study covers the market share revenue/market share/volume for each of the segments, regions and countries catering to global Hormone Refractory Prostate Cancer (HRPCA) market. The regions analyzed for the market are Europe, Asia Pacific, North America, South America and Middle East & Africa. Furthermore, the regions are further analyzed at the country level.
  • The report encompasses with the relative data & information, which have been validated by the leading industry professionals and experts all across the globe. The research report also delivers an outline of the attractiveness of treatment type, end user and regions which are deduced and formulatedon the basis of theirgrowth rate (CAGR), market size, and attractiveness by analyzing the present and future prospects to fathommarket growth and development in future.
  • The report illustrates the detailed (both quantitative and qualitative) analysis of historical data, revenues, key developments, along with the crucial strategies adopted by key organizations catering to global Hormone Refractory Prostate Cancer (HRPCA) market. This offers vital and in depth insights in order to depict the overall market scenario.
  • The report offers the detailed study for the company profiles of key organizations operating in the global Hormone Refractory Prostate Cancer (HRPCA) market and a comparative assessment based on their product offering, business overviews, geographic presence, business strategies, segment market share, product development &innovations, recent developments, joint venture, partnerships, mergers & acquisitions, strategic alliances, SWOT analysis, and key financial information. This helps in evaluating the overall competition present in the market scenario.
  • The report provides an elaborative assessment of the porter’s five forces analysis coupled with SWOT analysis so as to provide business related data and information’s. Porter’s five forces model is analyzed to understand the overall competitive scenario that is prevailing in the market. Additionally, the SWOT analysis identifies both the positive and negative attributes of the market development which influences the company growth and development in order to sustain and survive in the long run.
  • Along with that, the report also focuses on the market related driving factors, growth limitations (restraints), potential industry opportunities, significant trends and development which acts as a key potential for the investors.
  • Potential growth prospects along with the penetration rate analysis of the products (market related i.e., global Hormone Refractory Prostate Cancer (HRPCA) market) is covered in order to comprehend the adoption rate and evaluate the market size.

Frequesntly Asked Questions

As per The Brainy Insights, the size of the hormone refractory prostate cancer (HRPCA) market was valued at USD 7.13 billion in 2020 and is anticipated to reach USD 18.35 billion by 2028.

Global hormone refractory prostate cancer (HRPCA) market is growing at a CAGR of 9.64% during the forecast period 2021-2028.

The global hormone refractory prostate cancer (HRPCA) market has been segmented based on treatment type, end user and regions. The hormonal therapy segment held a largest market share.

The North America region emerged as the largest market for the hormone refractory prostate cancer (HRPCA).

Promising pipeline drugs is the key driving factor for the hormone refractory prostate cancer (HRPCA)market.

Treatment in emerging economies will provide huge opportunities to the market.

Key players are AbbVie Inc., AcceleronPharma Inc., AB Science SA, AstraZeneca Plc., AstellasPharma Inc., Boston Biomedical Inc., Dendreon Corporation

1. Introduction
    1.1. Objectives of the Study
    1.2. Market Definition
    1.3. Research Scope
    1.4. Currency
    1.5. Key Target Audience

2. Research Methodology and Assumptions

3. Executive Summary

4. Premium Insights
    4.1. Porter’s Five Forces Analysis
    4.2. Value Chain Analysis
    4.3. Top Investment Pockets
          4.3.1. Market Attractiveness Analysis By Treatment Type
          4.3.2. Market Attractiveness Analysis By End User
          4.3.3. Market Attractiveness Analysis By Region
    4.4. Industry Trends

5. Market Dynamics
    5.1. Market Evaluation
    5.2. Drivers
          5.2.1. Promising pipeline drugs
          5.2.2. Evolving patterns of treatment with increase in patent awareness
    5.3. Restrains
          5.3.1. Premium pricing of CRPC drugs
    5.4. Opportunities
          5.4.1. Treatment in emerging economies

6. Global Hormone Refractory Prostate Cancer (HRPCA) Market Analysis and Forecast, By Treatment Type
    6.1. Segment Overview
    6.2. Chemotherapy
    6.3. Hormonal Therapy
    6.4. Immunotherapy
    6.5. Radiation therapy
    6.6. Surgery
    6.7. Others

7. Global Hormone Refractory Prostate Cancer (HRPCA) Market Analysis and Forecast, By End User
    7.1. Segment Overview
    7.2. Hospitals
    7.3. Ambulatory Surgical Centers
    7.4. Specialty Clinics
    7.5. Others

8. Global Hormone Refractory Prostate Cancer (HRPCA) Market Analysis and Forecast, By Regional Analysis
    8.1. Segment Overview
    8.2. North America
          8.2.1. U.S.
          8.2.2. Canada
          8.2.3. Mexico
    8.3. Europe
          8.3.1. Germany
          8.3.2. France
          8.3.3. U.K.
          8.3.4. Italy
          8.3.5. Spain
    8.4. Asia-Pacific
          8.4.1. Japan
          8.4.2. China
          8.4.3. India
    8.5. South America
          8.5.1. Brazil
    8.6. Middle East and Africa
          8.6.1. UAE
          8.6.2. South Africa

9. Global Hormone Refractory Prostate Cancer (HRPCA) Market-Competitive Landscape
    9.1. Overview
    9.2. Market Share of Key Players in GlobalHormone Refractory Prostate Cancer (HRPCA) Market
          9.2.1. Global Company Market Share
          9.2.2. North America Company Market Share
          9.2.3. Europe Company Market Share
          9.2.4. APAC Company Market Share
    9.3. Competitive Situations and Trends
          9.3.1. Product Launches and Developments
          9.3.2. Partnerships, Collaborations, and Agreements
          9.3.3. Mergers & Acquisitions
          9.3.4. Expansions

10. Company Profiles
    10.1. AbbVie Inc.
          10.1.1. Business Overview
          10.1.2. Company Snapshot
          10.1.3. Company Market Share Analysis
          10.1.4. Company Product Portfolio
          10.1.5. Recent Developments
          10.1.6. SWOT Analysis
    10.2. Acceleron Pharma Inc.
          10.2.1. Business Overview
          10.2.2. Company Snapshot
          10.2.3. Company Market Share Analysis
          10.2.4. Company Product Portfolio
          10.2.5. Recent Developments
          10.2.6. SWOT Analysis
    10.3. AB Science SA
          10.3.1. Business Overview
          10.3.2. Company Snapshot
          10.3.3. Company Market Share Analysis
          10.3.4. Company Product Portfolio
          10.3.5. Recent Developments
          10.3.6. SWOT Analysis
    10.4. AstraZeneca Plc.
          10.4.1. Business Overview
          10.4.2. Company Snapshot
          10.4.3. Company Market Share Analysis
          10.4.4. Company Product Portfolio
          10.4.5. Recent Developments
          10.4.6. SWOT Analysis
    10.5. Astellas Pharma Inc.
          10.5.1. Business Overview
          10.5.2. Company Snapshot
          10.5.3. Company Market Share Analysis
          10.5.4. Company Product Portfolio
          10.5.5. Recent Developments
          10.5.6. SWOT Analysis
    10.6. Boston Biomedical Inc.
          10.6.1. Business Overview
          10.6.2. Company Snapshot
          10.6.3. Company Market Share Analysis
          10.6.4. Company Product Portfolio
          10.6.5. Recent Developments
          10.6.6. SWOT Analysis
    10.7. Dendreon Corporation
          10.7.1. Business Overview
          10.7.2. Company Snapshot
          10.7.3. Company Market Share Analysis
          10.7.4. Company Product Portfolio
          10.7.5. Recent Developments
          10.7.6. SWOT Analysis
    10.8. Sanofi S.A
          10.8.1. Business Overview
          10.8.2. Company Snapshot
          10.8.3. Company Market Share Analysis
          10.8.4. Company Product Portfolio
          10.8.5. Recent Developments
          10.8.6. SWOT Analysis
    10.9. Johnson & Johnson
          10.9.1. Business Overview
          10.9.2. Company Snapshot
          10.9.3. Company Market Share Analysis
          10.9.4. Company Product Portfolio
          10.9.5. Recent Developments
          10.9.6. SWOT Analysis
    10.10. Bioverativ Inc
          10.10.1. Business Overview
          10.10.2. Company Snapshot
          10.10.3. Company Market Share Analysis
          10.10.4. Company Product Portfolio
          10.10.5. Recent Developments
          10.10.6. SWOT Analysis

List of Table

1. Global Hormone Refractory Prostate Cancer (HRPCA) Market, By Treatment Type, 2018-2028 (USD Billion)

2. Global Chemotherapy, Hormone Refractory Prostate Cancer (HRPCA) Market, By Region, 2018-2028 (USD Billion)

3. Global Hormonal Therapy, Hormone Refractory Prostate Cancer (HRPCA) Market, By Region, 2018-2028 (USD Billion)

4. Global Immunotherapy, Hormone Refractory Prostate Cancer (HRPCA) Market, By Region, 2018-2028 (USD Billion)

5. Global Radiation therapy, Hormone Refractory Prostate Cancer (HRPCA) Market, By Region, 2018-2028 (USD Billion)

6. Global Surgery, Hormone Refractory Prostate Cancer (HRPCA) Market, By Region, 2018-2028 (USD Billion)

7. Global Others, Hormone Refractory Prostate Cancer (HRPCA) Market, By Region, 2018-2028 (USD Billion)

8. Global Hormone Refractory Prostate Cancer (HRPCA) Market, By End User, 2018-2028 (USD Billion)

9. Global HospitalsHormone Refractory Prostate Cancer (HRPCA) Market, By Region, 2018-2028 (USD Billion)

10. Global Ambulatory Surgical Centers, Hormone Refractory Prostate Cancer (HRPCA) Market, By Region, 2018-2028 (USD Billion)

11. Global Specialty Clinics, Hormone Refractory Prostate Cancer (HRPCA) Market, By Region, 2018-2028 (USD Billion)

12. Global Others, Hormone Refractory Prostate Cancer (HRPCA) Market, By Region, 2018-2028 (USD Billion)

13. Global Hormone Refractory Prostate Cancer (HRPCA) Market, By Region, 2018-2028     (USD Billion)

14. Global Hormone Refractory Prostate Cancer (HRPCA) Market, By North America, 2018-2028 (USD Billion)

15. North America Hormone Refractory Prostate Cancer (HRPCA) Market, By Treatment Type, 2018-2028 (USD Billion)

16. North America Hormone Refractory Prostate Cancer (HRPCA) Market, By End User, 2018-2028 (USD Billion)

17. U.S. Hormone Refractory Prostate Cancer (HRPCA) Market, By Treatment Type, 2018-2028 (USD Billion)

18. U.S. Hormone Refractory Prostate Cancer (HRPCA) Market, By End User, 2018-2028 (USD Billion)

19. Canada Hormone Refractory Prostate Cancer (HRPCA) Market, By Treatment Type, 2018-2028 (USD Billion)

20. Canada Hormone Refractory Prostate Cancer (HRPCA) Market, By End User, 2018-2028 (USD Billion)

21. Mexico Hormone Refractory Prostate Cancer (HRPCA) Market, By Treatment Type, 2018-2028 (USD Billion)

22. Mexico Hormone Refractory Prostate Cancer (HRPCA) Market, By End User, 2018-2028 (USD Billion)

23. Europe Hormone Refractory Prostate Cancer (HRPCA) Market, By Treatment Type, 2018-2028 (USD Billion)

24. Europe Hormone Refractory Prostate Cancer (HRPCA) Market, By End User, 2018-2028 (USD Billion)

25. Germany Hormone Refractory Prostate Cancer (HRPCA) Market, By Treatment Type, 2018-2028 (USD Billion)

26. Germany Hormone Refractory Prostate Cancer (HRPCA) Market, By End User, 2018-2028 (USD Billion)

27. France Hormone Refractory Prostate Cancer (HRPCA) Market, By Treatment Type, 2018-2028 (USD Billion)

28. France Hormone Refractory Prostate Cancer (HRPCA) Market, By End User, 2018-2028 (USD Billion)

29. U.K. Hormone Refractory Prostate Cancer (HRPCA) Market, By Treatment Type, 2018-2028 (USD Billion)

30. U.K. Hormone Refractory Prostate Cancer (HRPCA) Market, By End User, 2018-2028     (USD Billion)

31. Italy Hormone Refractory Prostate Cancer (HRPCA) Market, By Treatment Type, 2018-2028 (USD Billion)

32. Italy Hormone Refractory Prostate Cancer (HRPCA) Market, By End User, 2018-2028     (USD Billion)

33. Spain Hormone Refractory Prostate Cancer (HRPCA) Market, By Treatment Type, 2018-2028 (USD Billion)

34. Spain Hormone Refractory Prostate Cancer (HRPCA) Market, By End User, 2018-2028    (USD Billion)

35. Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Market, By Treatment Type, 2018-2028 (USD Billion)

36. Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Market, By End User, 2018-2028 (USD Billion)

37. Japan Hormone Refractory Prostate Cancer (HRPCA) Market, By Treatment Type, 2018-2028 (USD Billion)

38. Japan Hormone Refractory Prostate Cancer (HRPCA) Market, By End User, 2018-2028   (USD Billion)

39. China Hormone Refractory Prostate Cancer (HRPCA) Market, By Treatment Type, 2018-2028 (USD Billion)

40. China Hormone Refractory Prostate Cancer (HRPCA) Market, By End User, 2018-2028   (USD Billion)

41. India Hormone Refractory Prostate Cancer (HRPCA) Market, By Treatment Type, 2018-2028 (USD Billion)

42. India Hormone Refractory Prostate Cancer (HRPCA) Market, By End User, 2018-2028 (USD Billion)

43. South America Hormone Refractory Prostate Cancer (HRPCA) Market, By Treatment Type, 2018-2028 (USD Billion)

44. South America Hormone Refractory Prostate Cancer (HRPCA) Market, By End User, 2018-2028 (USD Billion)

45. Brazil Hormone Refractory Prostate Cancer (HRPCA) Market, By Treatment Type, 2018-2028 (USD Billion)

46. Brazil Hormone Refractory Prostate Cancer (HRPCA) Market, By End User, 2018-2028   (USD Billion)

47. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Market, By Treatment Type, 2018-2028 (USD Billion)

48. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Market, By End User, 2018-2028 (USD Billion)

49. UAE Hormone Refractory Prostate Cancer (HRPCA) Market, By Treatment Type, 2018-2028 (USD Billion)

50. UAE Hormone Refractory Prostate Cancer (HRPCA) Market, By End User, 2018-2028     (USD Billion)

51. South Africa Hormone Refractory Prostate Cancer (HRPCA) Market, By Treatment Type, 2018-2028 (USD Billion)

52. South Africa Hormone Refractory Prostate Cancer (HRPCA) Market, By End User, 2018-2028 (USD Billion) 

List of Figures 

1. Global Hormone Refractory Prostate Cancer (HRPCA) Market Segmentation

2. Hormone Refractory Prostate Cancer (HRPCA) Market: Research Methodology

3. Market Size Estimation Methodology: Bottom-Up Approach

4. Market Size Estimation Methodology: Top-Down Approach

5. Data Triangulation

6. Porter’s Five Forces Analysis 

7. Value Chain Analysis 

8. Global Hormone Refractory Prostate Cancer (HRPCA) Market Attractiveness Analysis By Treatment Type

9. Global Hormone Refractory Prostate Cancer (HRPCA) Market Attractiveness Analysis By End User

10. Global Hormone Refractory Prostate Cancer (HRPCA) Market Attractiveness Analysis By Region

11. Global Hormone Refractory Prostate Cancer (HRPCA) Market: Dynamics

12. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Treatment Type(2021 & 2028  )

13. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by End User(2021 & 2028  )

14. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Regions (2021 & 2028  )

15. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Company (2020)

This study forecasts revenue at global, regional, and country levels from 2018 to 2028. The Brainy Insights has segmented the global Hormone Refractory Prostate Cancer (HRPCA) market on the basis of below mentioned segments:

Global Hormone Refractory Prostate Cancer (HRPCA) Market by Treatment Type:

  • Chemotherapy
  • Hormonal Therapy
  • Immunotherapy
  • Radiation therapy
  • Surgery
  • Others

Global Hormone Refractory Prostate Cancer (HRPCA) Market by End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Others

Global Hormone Refractory Prostate Cancer (HRPCA) Market by Region:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
  • Asia-Pacific
    • Japan
    • China
    • India
  • South America
    • Brazil
  • Middle East and Africa  
    • UAE
    • South Africa

Methodology

Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision. 

Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.

The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.

Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:

MARKET RESEARCH PROCESS

Data Procurement:

The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.

The data procurement stage involves in data gathering and collecting through various data sources.

This stage involves in extensive research. These data sources includes:

Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:

  • The organizational databases such as D&B Hoovers, and Bloomberg that helps us to identify the competitive scenario of the key market players/organizations along with the financial information.
  • Industry/Market databases such as Statista, and Factiva provides market/industry insights and deduce certain formulations. 
  • We also have contractual agreements with various reputed data providers and third party vendors who provide information which are not limited to:
    • Import & Export Data
    • Business Trade Information
    • Usage rates of a particular product/service on certain demographics mainly focusing on the unmet prerequisites

Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.

Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.

The supply side for a domain specific market is analysed by:

  • Estimating and projecting penetration rates through analysing product attributes, availability of internal and external substitutes, followed by pricing analysis of the product.
  • Experiential assessment of year-on-year sales of the product by conducting interviews.

The demand side for the market is estimated through:

  • Evaluating the penetration level and usage rates of the product.
  • Referring to the historical data to determine the growth rate and evaluate the industry trends

In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.

Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:

  • Applying demographic along with psychographic segmentation for market evaluation
  • Determining the Micro and Macro-economic indicators for each region 
  • Examining the industry indicators prevailing in the market. 

Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:

  • Data Screening: Data screening is the process of scrutinising data/information collected from primary research for errors and amending those collected data before data integration method. The screening involves in examining raw data, identifying errors and dealing with missing data. The purpose of the data screening is to ensure data is correctly entered or not. The Brainy Insights employs objective and systematic data screening grades involving repeated cycles of quality checks, screening and suspect analysis.
  • Data Integration: Integrating multiple data streams is necessary to produce research studies that provide in-depth picture to the clients. These data streams come from multiple research studies and our in house database. After screening of the data, our analysts conduct creative integration of data sets, optimizing connections between integrated surveys and syndicated data sources. There are mainly 2 research approaches that we follow in order to integrate our data; top down approach and bottom up approach.

Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.

This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.

Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.

The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:

  • CXOs and VPs of leading companies’ specific to sector
  • Purchasing managers, technical personnel, end-users
  • Key opinion leaders such as investment bankers, and industry consultants

Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.

Some Facts About The Brainy Insights

50%

Free Customization

300+

Fortune 500 Clients

1

Free Yearly Update On Purchase Of Multi/Corporate License

900+

Companies Served Till Date